$DRTS News

Alpha Tau Medical and Tolmar Form U.S. Prostate Cancer Partnership To Commercialize Alpha DaRT Therapy With Exclusive Rights And Long-Term Revenue Sharing Deal

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

Alpha Tau Medical Presents Overall Survival, Safety Results From Pooled Analysis Of Three Prospective Phase I/II Clinical Studies Evaluating EUS-Guided Intratumoral Alpha Dart Treatment In PDAC Patients At 2026 ASCO Annual Meeting

Barclays Initiates Coverage On Alpha Tau Medical with Overweight Rating, Announces Price Target of $15

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target

Piper Sandler Maintains Neutral on Alpha Tau Medical, Raises Price Target to $8

CORRECTION: Alpha Tau Medical Q1 EPS $(0.26) Misses $(0.12) Estimate

Ladenburg Thalmann Maintains Buy on Alpha Tau Medical, Raises Price Target to $14

HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $15

Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally

Alpha Tau Medical Treats First Pancreatic Cancer Patient In Feasibility And Safety Study For Alpha-Emitter Radiation Treatment For Pancreatic Tumors

Alpha Tau Medical Announces Presentation Of Updated Pooled Results From Two First-In-Human Clinical Trials Of Alpha Dart In Pancreatic Ductal Adenocarcinoma At Digestive Disease Week

Alpha Tau Medical Says Abstract Showcasing Combined Results From Three Clinical Studies Evaluating Alpha Radiotherapy For Advanced Pancreatic Cancer Accepted At 2026 ASCO Annual Meeting

Alpha Tau Medical Announces FDA Approval Of Investigational Device Exemption Supplement To Its U.S. IMPACT Trial Evaluating Alpha DaRT To Treat Unresectable Locally Advanced Or Metastatic Pancreatic Adenocarcinoma

Alpha Tau Medical Announces Treatment Of First Patient In ACAPELLA, European Multicenter Clinical Trial Evaluating Alpha DaRT Combined With Capecitabine For Patients With Inoperable LAPC

Alpha Tau Medical: 2026 Is The Breakthrough Year

Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Citigroup Maintains Buy on Alpha Tau Medical, Raises Price Target to $9

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $12 Price Target